Curis Inc (CRIS) stock
CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.45−0.13 (-22.18%)
Close on Nov 13, 2026Market cap $930.08KP/E –Yield –
Curis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Curis's EPS for the twelve months ending Sep 30, 2025 was -$73.51. For fiscal 2025 it was -$11.60. The highest annual figure on record is $200.00 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.60 | – |
| FY2024 | Dec 31, 2024 | -$137.60 | – |
| FY2023 | Dec 31, 2023 | -$179.20 | – |
| FY2022 | Dec 31, 2022 | -$242.80 | -221.4% |
| FY2021 | Dec 31, 2021 | $200.00 | – |
| FY2020 | Dec 31, 2020 | -$244.00 | – |
| FY2019 | Dec 31, 2019 | -$388.00 | – |
| FY2018 | Dec 31, 2018 | -$392.00 | – |
| FY2017 | Dec 31, 2017 | -$716.00 | – |
| FY2016 | Dec 31, 2016 | -$900.00 | – |
| FY2015 | Dec 31, 2015 | -$960.00 | – |
| FY2014 | Dec 31, 2014 | -$440.00 | – |
| FY2013 | Dec 31, 2013 | -$300.00 | – |
| FY2012 | Dec 31, 2012 | -$420.00 | – |
| FY2011 | Dec 31, 2011 | -$260.00 | – |
| FY2010 | Dec 31, 2010 | -$120.00 | – |
| FY2009 | Dec 31, 2009 | -$300.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.94 | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.02 | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.00 | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.86 | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.61 | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.00 | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.04 | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.00 | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.60 | – |
| Q1 FY2024 | Mar 31, 2024 | -$41.00 | – |
| Q4 FY2023 | Dec 31, 2023 | -$40.54 | – |
| Q3 FY2023 | Sep 30, 2023 | -$42.60 | – |
| Q2 FY2023 | Jun 30, 2023 | -$49.40 | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.80 | – |
| Q4 FY2022 | Dec 31, 2022 | -$46.98 | – |
| Q3 FY2022 | Sep 30, 2022 | -$56.60 | – |
| Q2 FY2022 | Jun 30, 2022 | -$68.00 | – |
| Q1 FY2022 | Mar 31, 2022 | -$72.00 | – |
| Q3 FY2021 | Sep 30, 2021 | -$48.00 | – |
| Q2 FY2021 | Jun 30, 2021 | -$48.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.00 | – |
| Q4 FY2020 | Dec 31, 2020 | -$44.00 | – |
| Q3 FY2020 | Sep 30, 2020 | -$44.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$68.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$112.00 | – |
| Q4 FY2019 | Dec 31, 2019 | -$104.00 | – |
| Q3 FY2019 | Sep 30, 2019 | -$76.00 | – |
| Q2 FY2019 | Jun 30, 2019 | -$88.00 | – |
| Q1 FY2019 | Mar 31, 2019 | -$120.00 | – |
| Q4 FY2018 | Dec 31, 2018 | -$72.00 | – |
| Q3 FY2018 | Sep 30, 2018 | -$88.00 | – |
| Q2 FY2018 | Jun 30, 2018 | -$104.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$132.00 | – |
| Q4 FY2017 | Dec 31, 2017 | -$96.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$212.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$196.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$220.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$160.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?